These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17362404)

  • 1. Model averaging using fractional polynomials to estimate a safe level of exposure.
    Faes C; Aerts M; Geys H; Molenberghs G
    Risk Anal; 2007 Feb; 27(1):111-23. PubMed ID: 17362404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A probabilistic framework for non-cancer risk assessment.
    Chen JJ; Moon H; Kodell RL
    Regul Toxicol Pharmacol; 2007 Jun; 48(1):45-50. PubMed ID: 17166641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
    Zhu Y; Wang T; Jelsovsky JZ
    Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model averaging in microbial risk assessment using fractional polynomials.
    Namata H; Aerts M; Faes C; Teunis P
    Risk Anal; 2008 Aug; 28(4):891-905. PubMed ID: 18564995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model uncertainty and risk estimation for experimental studies of quantal responses.
    Bailer AJ; Noble RB; Wheeler MW
    Risk Anal; 2005 Apr; 25(2):291-9. PubMed ID: 15876205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exposure imprecision on estimation of the benchmark dose.
    Budtz-Jørgensen E; Keiding N; Grandjean P
    Risk Anal; 2004 Dec; 24(6):1689-96. PubMed ID: 15660622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A procedure for developing risk-based reference doses.
    Gaylor DW; Kodell RL
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing experimental designs for benchmark dose calculations for continuous endpoints.
    Kuljus K; von Rosen D; Sand S; Victorin K
    Risk Anal; 2006 Aug; 26(4):1031-43. PubMed ID: 16948695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quantitative methods of cancer risk assessment in exposure to chemicals].
    Szymczak W
    Med Pr; 2009; 60(3):215-21. PubMed ID: 19746890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of model-averaged BMDLs: a study of model averaging in dichotomous response risk estimation.
    Wheeler MW; Bailer AJ
    Risk Anal; 2007 Jun; 27(3):659-70. PubMed ID: 17640214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotonic Bayesian semiparametric benchmark dose analysis.
    Wheeler M; Bailer AJ
    Risk Anal; 2012 Jul; 32(7):1207-18. PubMed ID: 22385024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision of benchmark dose estimates for continuous (nonquantal) measurements of toxic effects.
    Gaylor DW; Chen JJ
    Regul Toxicol Pharmacol; 1996 Aug; 24(1 Pt 1):19-23. PubMed ID: 8921542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent number of implants and implications in developmental toxicity.
    Dunson DB
    Biometrics; 1998 Jun; 54(2):558-69. PubMed ID: 9629644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of BMD models in quantitative evaluation of carcinogenic risk].
    Szymczak W
    Med Pr; 1998; 49(6):579-87. PubMed ID: 10204147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
    Gocke E; Müller L; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of multivariable fractional polynomial models with selection of variables and transformations: a bootstrap investigation.
    Royston P; Sauerbrei W
    Stat Med; 2003 Feb; 22(4):639-59. PubMed ID: 12590419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a critical dose level for risk assessment: developments in benchmark dose analysis of continuous endpoints.
    Sand S; von Rosen D; Victorin K; Filipsson AF
    Toxicol Sci; 2006 Mar; 90(1):241-51. PubMed ID: 16322076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A parametric model for detecting hormetic effects in developmental toxicity studies.
    Hunt DL; Bowman D
    Risk Anal; 2004 Feb; 24(1):65-72. PubMed ID: 15028001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.